CD274 and non-small cell lung carcinoma: This study shows poor response of NSCLC to anti‐PD‐1 antibody retreatment (nivolumab/pembrolizumab) after initial treatment with anti‐PD‐L1 antibodies (atezolizumab/durvalumab).